SCHEMBL1423010

SCHEMBL1423010

CCc1cccc2c(C(c3ccc(C(F)(F)F)cc3)C3C(=O)OC(C)(C)OC3=O)c[nH]c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.37
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.35
KDR P35968 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 2/20 0.33
UBE2N P61088 1/20 0.33
HPGD P15428 1/20 0.33
HSD11B1 P28845 2/20 0.32
MC4R P32245 1/20 0.32
MC5R P33032 1/20 0.32
MC3R P41968 1/20 0.32
GAA P10253 1/20 0.30
RAB9A P51151 1/20 0.30
PDE2A O00408 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1349438 0.91 BACE1 (0.35) BACE1HSD11B1MC4RMC5RMC3R
SCHEMBL1347715 0.81 BACE1 (0.34) BACE1HSD11B1PDE2A
SCHEMBL1347675 0.79
SCHEMBL1349687 0.79
SCHEMBL1347809 0.78 PDE2A (0.33) BACE1PDE2A
SCHEMBL1349747 0.78
SCHEMBL1349039 0.74 MC4R (0.33) HSD11B1MC4RMC5RMC3RGAA
SCHEMBL1350056 0.74 RIPK1 (0.30)
SCHEMBL1349969 0.74 S1PR1 (0.32) PDE2A
SCHEMBL1423530 0.72 ALDH1A1 (0.40) USP2TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-28 US disclosed
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-28 US disclosed
EP-2297099-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF Bayer Schering Pharma Aktiengesellschaft (DE) 2011-03-23 EP disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof HTR3C, HTR3A, ADRB3 BACE1 2478/4885USP2 2062/4885TSHR 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.